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The treatment of rectal cancer has changed radically during
the last decade. The introduction of the surgical technique total
mesorectal excision (TME) worldwide has resulted in a decline of
local recurrence rate because more tumors were excised com-
pletely, along with the excision of regional metastatic disease in the
mesorectal fat. In addition, the role of neoadjuvant treatment
either by radiotherapy or by radiochemotherapy has been estab-
lished during the last 10 years. In Europe, overwhelming evidence
has been gathered from large randomized trials (Total Mesorectal
Excision trial [TME], Swedish Rectal Cancer Trial, and Cancer
Research UK [CR07]),1-3 with a total number of 4,427 patients,
showing that for primarily resectable rectal cancer, short-term
preoperative radiotherapy (5 Gy daily for 5 days) resulted in local
recurrence rates lower than 5%, especially in combination with
TME surgery. For locally advanced tumors, long-term radiother-
apy(approximately50Gy) incombinationwithneoadjuvantchem-
otherapy is the treatment of choice.4,5
The combination of the above-mentioned changes in therapy
results in improved prognosis of patients with rectal cancer, espe-
cially with respect to local recurrence, but these advances have not
yet been included in staging of rectal carcinoma. In fact, these
innovations in therapy call for a change in the approach of staging.
Because of the application of neoadjuvant therapy, both the func-
tion of staging systems and the factors used for staging have
changed, which complicates the current practice.
Initially, postoperative pathologic staging was used for the
prediction of prognosis as well as for the indication of adjuvant
therapy. At present, clinical staging determines whether and
which preoperative therapy should be applied, and postopera-
tive staging is used to evaluate the effects of therapy in addition
to the above-mentioned goals. The consequence of these
changes is a divergence between clinical TNM and pathologic
(p) TNM. Moreover, the current pTNM is essentially different
from the pTNM of the last century. Still, the staging system
for rectal cancer uses the same rules as Cuthbert Dukes pro-
posed in 1932.6
IMPACT OF NEOADJUVANT THERAPY
Long-term radiotherapy and chemoradiotherapy schemes are
aimed at tumor downstaging to facilitate complete surgical re-
moval. Pronounced changes in tumor histology are observed in the
operation specimen, and are indicative of tumor response or re-
gression. In many of these cases, the pT stage is lowered compared
with the initial cT stage, but it is not clear which of these two is the
best predictor for prognosis. The current guidelines of the Ameri-
can Joint Committee on Cancer TNM staging systems7,8 acknowl-
edge preoperative treatment by adding the prefix y, but the clinical
consequences are not clear.
The ypT stage can be used as ameasurement for tumor down-
staging, however, after locally advanced tumors are removed, tu-
mor remnants might be left behind in the surrounding tissue,
resulting in inadequate determination of T stage. Moreover, there
is a large variability between the pT3 tumors with regard to tumor
load. Alternatively, response can be indicated by determining the
grade of tumor regression. Various systems have been suggested to
grade tumor regression,9-11 but the majority are not able to dem-
onstrate a relation with prognosis. In addition, reproducibility of
regression grading is poor.11,12
Given that the goal of long-term neoadjuvant therapy is the
facilitationof surgical removal,we suggest inclusionof surgery-related
factors in the staging after this kind of treatment.
SURGICAL FACTORS IN THE 21st CENTURY
The recognition of TME as a superior surgical technique is preceded
by the recognition of circumferential margin (CRM) involvement as
the best prognostic factor, not only for local recurrence, but also for
development ofmetastases and for survival. A recent reviewwith data
of more than 17,500 patients (unpublished data: Nagtegaal ID and
Quirke P, “What role for the circumferential margin in the modern
treatment of rectal cancer,” 2007) demonstrated that the prognostic
JOURNAL OF CLINICAL ONCOLOGY COMMENTS AND CONTROVERSIES
VOLUME 25  NUMBER 13  MAY 1 2007
1647Journal of Clinical Oncology, Vol 25, No 13 (May 1), 2007: pp 1647-1650
DOI: 10.1200/JCO.2005.05.4825
from 131.174.248.56
Information downloaded from jco.ascopubs.org and provided by at UNIVERSITEITSBIBLIOTHEEK on November 12, 2012
Copyright © 2007 American Society of Clinical Oncology. All rights reserved.
value of an involvedCRM for local recurrence is even stronger after
neoadjuvant therapy (hazard ratio, 6.3; 95% CI, 3.6 to 16.7 versus
hazard ratio, 2.2; 95%CI, 1.5 to 3.2 without neoadjuvant therapy).
ApositiveCRMafter surgerycanbecausedbyvarious factors, the
most important ofwhich are suboptimal quality of surgery, aggressive
tumor growth, therapy resistance, and inadequate preoperative imag-
ing. The quality of surgery is analyzed by the assessment of plane of
resection. This is correlated with both local recurrence and overall
survival, and its value has been confirmed recently in another large
multicenter trial.13Thefinding thatCRMinvolvement canpredict the
development of distantmetastases as well as survivalmay suggest that
aggressive tumor growth ismost important.14However, the fact that a
positive CRM due to poor-quality surgery also is correlated with
survival14 indicates that for prognosis, the cause of margin involve-
ment does not seem tomatter.14
STAGING SYSTEMS: WHERE SHOULD WE GO?
In the era of neoadjuvant therapy, the existing staging systems are
suboptimal. There is a need for the implementation of treatment-
related factors, which will improve both staging and prediction of
prognosis.15 The result of treatment is one of the most relevant fea-
tures for predicting final outcome; therefore, modern staging systems
should take both tumor and treatment factors into account. The
incorporationof these factors, of course, should be basedon evidence.
Before we can propose a new staging system, we have to address the
followingquestions:Which factors canpredict prognosis reliably?Are
these factors generally applicable? Can these factors be assessed in a
reliable and simple way? Is there a combination of factors that divides
patients adequately in large, homogeneous groups with highly diver-
gent survival curves?
Which Factors Can Predict Prognosis Reliably?
First, we have to question the value and reliability of established
tumor factors such as invasion depth and lymph node status in the
current situation. Asmentioned, the reliability and relevance of ypT is
questionable. The presence of lymph node metastases after neoadju-
vant therapy is still a major prognostic factor.16-18 However, an un-
knownnumberofnode-negativepatientswill havehadpositivenodes
that are sterilizedbyneoadjuvant therapy. Therefore, ypN0 consists of
a heterogeneous group of patients who were initially node negative
and patients whose metastatic tumors responded well to treatment.
Although the meaning of ypN0 might be different from that of pN0,
the prognostic impact is still applicable. However, a multivariate
analysis of 182 patients18 suggests that after neoadjuvant therapy,
CRM is more important for prognosis than lymph node involve-
ment. Given that neoadjuvant therapy is mainly aimed on local
control, at present, we can leave the presence of metastatic disease
(TNM IV) out of this discussion.
Treatment-related factors areCRM, tumor regression, and qual-
ity of surgery. The results of tumor regression grading are variable and
no consistent relation with prognosis has been demonstrated. More-
over, four different studies including a total of 490 patients demon-
strated the superiority of CRM assessment above regression
grading.12,19-21 Quality of surgery evaluation in two independent ran-
domized trials demonstrates prognostic value for both local recur-
rence and survival.13,14 However, CRM involvement is more
important than plane of surgery.14
Finally, there are many biomarkers described, but none of them
have reached the standard assessment of rectal cancer specimens and
therefore remain beyond the scope of this commentary.
Are These Factors Generally Applicable?
Although preoperative neoadjuvant therapy will be applied in
most occurrences of rectal cancer, some patients will undergo surgery
right away. The new staging should be applicable in all situations.
Tumor invasion, lymph node metastases, CRM involvement, and
quality of surgery can be evaluated with and without neoadjuvant
therapy and in any laboratory of pathology. One could argue that this
is the case for tumor regression aswell, and thatwithout therapy there
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Fig 1. Hazard ratio and 95% confidence interval of TNM staging versus a new
staging method based on nodal and circumferential margin status (NCRM). (A)
TME trial (n  1530; follow-up 67 months). (B) Polish rectal cancer trial (n  316;
follow-up 48 months). y, preoperative treatment; p, pathologic.
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will be no regression. As a result, although the absence of regression
after therapy may indicate poor prognosis, the absence of regression
without therapy has nomeaning at all.
Can These Factors Be Determined in a Reliable and
Simple Way?
The stage of the tumor is relatively simple to determine pro-
vided that an adequate sampling of the tumor area is performed.
Especially for the determination of ypT0 (complete regression), a
standardized protocol is required. Careful examination of the re-
section specimen will reveal possible involvement of the circum-
ferential margin and presence of lymph node metastasis. Detailed
protocols are available.22,23
Determination of tumor regression is much more difficult and
reproducibility studies show  values as low as 0.30.12 One of the
reasons is that there is no consensus about the definitions that should
be used, apart from the definition of complete response. It is disap-
pointing that todate, noneof the reported studies used this definition.
Is There a Combination of Factors That Adequately
Divides Patients in Large, Homogeneous Groups
With Highly Divergent Survival Curves?
In a recent study24 based on the data from a randomized clinical
trial,1 we demonstrated in amultivariatemodel that CRMrather than
pT stage is important for the prognosis of rectal cancer. This is true for
patients without preoperative treatment as well as for patients treated
with short-termpreoperative radiotherapy.On the basis of these find-
ings, we designed a staging system including both CRM (treatment-
related factor) and nodal status (tumor-related factor; Fig 1). Using
this system, we created highly divergent survival curves, with a small
group of patients with a poor prognosis (n  93; 7%; 37% 5-year
survival) anda large groupofpatientswith agoodprognosis (n753;
57%;92%5-year survival).Weconfirmedourfindings in an indepen-
dent data set derived fromanother randomized trial25 (Fig 1B). In this
group of patients (with short-term and long-term neoadjuvant ther-
apy) thenewstaging systemperformed significantlybetter thanTNM.
In conclusion, inmodern staging of cancer there should be an
important place for treatment-related factors, given that the result
of treatment is one of the most important prognostic factors. For
rectal cancer we demonstrated that in the era of neoadjuvant
therapy, free circumferential resection margins are more impor-
tant than the classic factor of invasion depth, and that incorpora-
tion of this factor in staging systems leads to better prediction of
prognosis and selection of patients.
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